The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

The FDA had given Pfizer and Moderna until May 17 to propose changes to the labels of their COVID-19 vaccines or challenge ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

"BioNTech to invest up to $1.34bn in UK R&D" was originally created and published by Pharmaceutical Technology, a GlobalData ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...